for Universities

Your Technology Transfer Office faces numerous
portfolio prioritization and monetization challenges.
Your Technology Transfer Office faces numerous
portfolio prioritization and monetization challenges.
Your licensing and R&D strategies rely on
a solid, unbiased understanding of your IP.
Understanding the commercial potential within your IP portfolio and fully aligning it with your corporate strategy is essential to exploiting and maximizing its value. Proper management of your portfolio is critical when attempting to identify the "stale" IP vs the "growth-opportunity" IP.
Years
of IP Evaluation
Experience
Analyze your technology to gauge commercialization readiness and potential risks.
Identify top competitors, directly competing patents & potential infringement risks.
Determine market size and potential for growth in various verticals using key indicators.
Uncover potential partnering opportunities from market and competitive landscape information.
Our client, a small US-based pharmaceutical company, was uncertain whether to continue funding their innovative women’s health drug candidate, currently in Phase II clinical trials, as they were unable to judge its market potential. They reached out to IP Technology Exchange, requesting we apply our unique Technology & Market Assessment methodology to evaluate the candidate and judge its market viability.
Based on our proprietary methodologies and algorithms, including examination of company and inventor backgrounds, patent and non-patent literature searches, historical market data, market projections, and other data, we were able to provide the client with an information-rich yet easily digested report detailing the current potential of their technology platform and its associated IP.
Our assessment validated their expectations regarding the competitive landscape, market penetration, potential gross licensing revenue, and other technology and business considerations. Empowering our client with this independent third-party analysis allowed them to continue funding their R&D program with confidence.